COMPASS PATHWAYS PLC (CMPS)

COMPASS Pathways (CMPS) Shares Cross Below 200 DMA

Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare Conference

LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to...

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors

David Norton Assumes Role of Interim Board Chair while the Company Runs a Global Search for a New Chair

The Next Great Biotech Boom Has Arrived

EQNX::TICKER_START (NYSE:JNJ),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:ATAI),(NYSE:ABBV) EQNX::TICKER_END

3 Biopharma Stocks You Don't Want to Miss in the New Bull Market

All three have exciting programs on the way.

Compass Pathways Plc (CMPS) Q4 2023 Earnings Call Transcript

CMPS earnings call for the period ending December 31, 2023.

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights

LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Highlights: COMP360 phase 3 pivotal program ongoing; COMP005 trial top-line data now expected in fourth...

Penny Power Players: 3 Stocks to Watch in the Microcap Arena

Dive into three microcap stocks set to skyrocket with innovative strategies and sector leadership. Don't miss out.

Compass Pathways to participate in upcoming TD Cowen investor conference

LONDON, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to...

Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024

LONDON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to...

Mental Health Mavericks: 3 Stocks Changing the Game

Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money.

Wall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen.

The lofty target is closer to being within reach than it may seem at first.

Why Is MindMed (MNMD) Stock Up 8% Today?

MindMed and other psychedelic stocks are rising today on news of an FDA priority review. Here's what this means for MNMD stock and its peers.

Psychedelic stocks gain after FDA priority review for MDMA therapy (NYSE:CYBN)

The FDA priority review for an MDMA-linked therapy leads to a surge in shares of psychedelic medicine companies such as Mind Medicine (MNMD). Read more here.

COMPASS Pathways director discloses sale of over 85K shares (NASDAQ:CMPS)

COMPASS Pathways director sells over 85k shares worth $902k; CMPS stock drops 6%. Total insider trades in the past three months reach 375k shares.

Compass Pathways to participate in upcoming Oppenheimer investor conference

LONDON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to...